Home » Topics » BioWorld Science

BioWorld Science
RSS

Imugene reports early data from trial of IMU-131 in metastatic gastric cancer

Feb. 7, 2018

Durvalumab/tremelimumab/nab-paclitaxel/gemcitabine regimen well tolerated in metastatic PDAC

Feb. 7, 2018

ContraVir Pharmaceuticals' TXL safe, well tolerated in phase I study

Feb. 7, 2018

NetVation DL Medicine, Pfizer enter research collaboration

Feb. 7, 2018

STAT3 shown as potential therapeutic target for gastroenteropancreatic neuroendocrine tumors

Feb. 7, 2018

Synairgen initiates phase II trial of inhaled SNG-001 in COPD

Feb. 7, 2018

Roche profiles pipeline progress of fourth quarter 2017

Feb. 7, 2018

Astellas divulges new melanocortin MC4 receptor agonists

Feb. 7, 2018

Novel 5-HT7 receptor agonists identified at the Institute of Pharmacology

Feb. 7, 2018

AstraZeneca's application to expand Tagrisso indication in Japan granted priority review

Feb. 7, 2018

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 13, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...